ClinicalTrials.gg
RecruitingNCT07631598BISTROUpdated Oct 1, 2026

Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses

An interventional study of Standard of Care Referral and Low Threshold Buprenorphine in Opioid Use Disorder, Opioid Use Disorder, Severe and Opioid Use Disorder, Moderate, sponsored by Montefiore Medical Center. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Montefiore Medical Center · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 1, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
512
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Opioid-Related Disorders by Montefiore Medical Center — 3 open to participants now, 3 under way, 1 of them phase 3. Opioid-Related Disorders · Montefiore Medical Center.

Planned enrollment
Largest of 10
512 · median 27
Started
2026
with 2 others
No phase
5 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Opioid-Related Disorders by Montefiore Medical Center, this one has the largest planned enrollment, is one of 3 that started in 2026, is one of 5 with no phase, and was the 10th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

3 of the 10 studies in Opioid-Related Disorders by Montefiore Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Opioid-Related Disorders by Montefiore Medical Center, or all of them as a file.
02

Study summary

This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine treatment providers. Buprenorphine is a medication that helps reduce opioid cravings and withdrawal symptoms.

The study compares two ways of connecting people to treatment:

Referral to a community treatment provider (usual care before the new program begins).

Onsite, low-threshold buprenorphine treatment at the SSP, which allows participants to start medication quickly and without having to establish care at another provider.

Participants will be adults who have opioid use disorder and are SSP clients. Each SSP will begin offering the new onsite buprenorphine program at different times during the study. Researchers will collect information before and after the new program begins to see how it affects treatment engagement and health outcomes.

The study will also examine how easy or difficult it is for SSPs to start and run the new program, how acceptable it is to staff and participants, and whether it is cost-effective.

The overall goal is to find better ways to expand access to life-saving opioid treatment in community-based settings.

Read the detailed description

This is a Type 1 hybrid effectiveness-implementation study designed to evaluate the impact and feasibility of implementing low-threshold buprenorphine (BUP) treatment at syringe service programs (SSPs) in order to improve access to and retention in medications for opioid use disorder (MOUD) treatment among people with moderate to severe opioid use disorder (OUD). The study seeks to understand whether the low-threshold approach improves participant-level outcomes and how SSPs can successfully implement and sustain this model.

Study Design

The study uses a cluster randomized stepped wedge design, in which eight SSPs will be randomly and sequentially assigned to begin implementing the low-threshold BUP program until all sites have transitioned from the referral condition to the intervention condition. This design allows each site to serve as its own control and ensures equitable access to the intervention over time. The stepped wedge design also facilitates examination of temporal effects, while accounting for differences in local environments and SSP readiness for implementation.

Participants will be recruited across the eight SSPs in different geographic regions of the United States. SSPs will be selected to represent a range of community types (urban, suburban, and rural) and to reflect varying policy environments related to MOUD access.

Study Rationale and Background

Despite robust evidence that buprenorphine reduces overdose deaths and improves recovery outcomes, access to this medication remains limited, especially among people who use drugs and have difficulty navigating the healthcare system. Low-threshold buprenorphine models aim to reduce barriers by emphasizing same-day access, flexibility, and a treatment orientation that meets participants "where they are."

SSPs provide a trusted, nonjudgmental environment and are uniquely positioned to engage individuals who are at highest risk for overdose and least likely to access formal treatment. Integrating buprenorphine prescribing directly within SSPs could substantially expand access to life-saving treatment in community settings.

Study Objectives

Primary Objective:

To evaluate the effectiveness of low-threshold BUP treatment at SSPs compared to treatment as usual (TAU) for increasing 3-month retention in buprenorphine treatment.

Secondary Objectives:

Assess buprenorphine adherence, additional OUD treatment outcomes, and health-related quality of life.

Examine the cost-effectiveness of implementing low-threshold BUP at SSPs from both payer and societal perspectives.

Characterize implementation outcomes-adoption, acceptability, appropriateness, feasibility, reach, fidelity, and sustainability-across diverse SSP settings.

Exploratory Objectives:

Explore participant-level moderators (e.g., polysubstance use, co-occurring mental health conditions, housing status, rurality) that may predict outcomes or differential intervention effects.

Identify contextual determinants (organizational capacity, policy environment, leadership engagement) associated with successful SSP implementation.

Study Procedures

Participants will complete study assessments at baseline, 1 month, 3 months, and 6 months post-enrollment. Measures will include substance use patterns, treatment engagement, overdose events, hospitalizations, and self-reported recovery activities. Laboratory-confirmed urine drug screens will be used to verify buprenorphine adherence.

Pre-implementation (Treatment-as-Usual) Prior to implementing the low-threshold BUP model, SSPs will provide standard care, which includes referral to community MOUD providers for BUP treatment.

Post-implementation (Low-Threshold BUP Program) Once implementation begins, SSPs will offer onsite BUP treatment directly through trained prescribers and peer outreach workers. Clients identified as eligible and interested will receive a medical evaluation from a study clinician (SC), including assessment for contraindications, education on BUP use, and initiation via home induction or observed dosing as appropriate.

Follow-up visits will occur approximately every 4 weeks for 6 months and include focused psychosocial counseling, urine drug screening (when requested by the study clinician), and continued prescription management. Both in-person and telehealth models may be used to enhance accessibility. Participants may use any FDA-approved formulation of buprenorphine, including injectable long-acting formulations, based on shared decision-making between study clinician and participant.

Implementation Facilitation Strategy

To support successful and sustainable adoption of the low-threshold BUP model, the study's Lead Node (LN) will develop and deliver an Implementation Facilitation Package. This package will include:

Structured training for SSP staff and clinicians on low-threshold buprenorphine principles and program logistics.

Coaching on identifying a site champion, hiring or engaging a prescriber, and establishing clear protocols for medication management.

Ongoing facilitation meetings between the LN and SSP implementation teams (champion, prescriber, peer outreach worker) to troubleshoot challenges, monitor fidelity, and adapt workflows.

Tools for tracking and sustaining reach, fidelity, and acceptability over time.

Hypotheses and Analytical Approach

The central hypothesis is that embedding low-threshold buprenorphine treatment within SSPs will improve engagement and retention in MOUD compared to standard referral pathways. Analyses will use mixed-effects regression models accounting for site-level clustering and time effects. Effectiveness analyses will focus on 3-month retention as the primary outcome, with sensitivity analyses at 6 months. Cost-effectiveness analyses will use quality-adjusted life years (QALYs) as the main effectiveness measure.

Implementation analyses will use the Consolidated Framework for Implementation Research (CFIR) and Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) frameworks to identify determinants, measure outcomes, and map facilitation processes. Qualitative interviews with staff and participants will complement quantitative metrics, offering a comprehensive understanding of how and why the intervention succeeds or encounters barriers.

Expected Impact

This study addresses a critical public health need by testing a scalable, community-driven model of OUD treatment. If the low-threshold SSP-based buprenorphine program is found to be effective and cost-efficient, the Implementation Facilitation Package developed through this study will serve as a replicable framework for dissemination to SSPs or other community-based settings nationwide. The findings have the potential to directly inform national strategies for expanding access to evidence-based treatment, reducing overdose deaths, and promoting patient-centered care.

03

Conditions studied

  • Opioid Use Disorder
  • Opioid Use Disorder, Severe
  • Opioid Use Disorder, Moderate

Keywords

  • Buprenorphine
  • Overdose Prevention
  • Low-Threshold Treatment
  • Community-Based Treatment
  • Medication for Opioid Use Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years old;
  2. Meet criteria for moderate or severe OUD;
  3. Interest in receiving buprenorphine treatment;
  4. Speaks English or Spanish;
  5. Currently an SSP client at the time of enrollment;
  6. Ability to provide .

Exclusion criteria

Exclusion Criteria:

  1. Current use of prescribed opioid agonist treatment, as assessed by self-report, at the time of enrollment;
  2. Unstable mental health or medical condition that requires an immediate clinical evaluation or higher level of care;
  3. Allergy to buprenorphine;
  4. Currently detained in jail, prison, residential substance use treatment facility, or other overnight facility as required by court of law. or have pending legal action that could prevent participation on study activities.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
512 participants (estimated)

Study arms

  • Active comparator
    Treatment As Usual (TAU)

    Participants enrolled before the intervention is implemented at each syringe service program (SSP) will receive standard of care, consisting of referral to community-based buprenorphine treatment providers. SSP staff will offer information and referral support but will not provide on-site buprenorphine treatment or prescribing.

    Other: Standard of Care Referral

  • Experimental
    Low-threshold Buprenorphine (LTB)

    After implementation at each SSP site, participants will have access to on-site, low-threshold buprenorphine treatment integrated into SSP services. This model focuses on minimizing barriers to treatment initiation and retention and includes , flexible policies and procedures and collaboration with a peer outreach worker.

    Behavioral: Low Threshold Buprenorphine

Interventions

  • OtherStandard of Care Referral

    During the pre-implementation phase, SSP staff will refer participants with opioid use disorder to external community providers for buprenorphine treatment. Services offered include information, referral assistance, and linkage to care, but buprenorphine will not be initiated or managed at the SSP site.

    Also known as: TAU

  • BehavioralLow Threshold Buprenorphine

    During the post-implementation phase, SSPs will implement a low-threshold model of care for buprenorphine treatment. This model includes: Low barrier to entry Flexible scheduling and follow-up procedures Risk reduction counseling Collaboration with a peer outreach worker Training and technical assistance for SSP staff and clinicians to deliver care in non-traditional, low-barrier settings This intervention focuses on implementing and evaluating a service delivery model to expand access to medication for opioid use disorder within SSPs.

    Also known as: LTB

06

What researchers measure

Primary outcomes

  1. 3-month Buprenorphine treatment retention (3-month retention)

    Buprenorphine (BUP) treatment retention will be defined as having an active buprenorphine prescription between baseline and 1-month and between the 1-month (days 1-30) and 3-month (days 31-90) time points. Participants will be asked to provide evidence of BUP prescriptions at study visits (i.e., confirmed prescriptions). If a participant receives a second BUP prescription before the 1-month follow-up and the number of days dispensed covers dates after day 30 (i.e., carries over into the 31-90 days interval), this participant will have met the primary outcome. The primary outcome will require at least one day of an active BUP prescription based on confirmed prescriptions within the 2 time-points. BUP treatment retention will be summarized as a binary ("Yes/No") variable. The number/percentage of participants who are retained at each timepoint will be summarized by arm. BUP treatment retention is the primary measure of effectiveness.

    Time frame: Between baseline and 1-month following intervention, and between baseline and 3-months following intervention

Secondary outcomes

  1. Buprenorphine Adherence

    Adherence to buprenorphine is a composite measure and will be defined as participants meeting the primary outcome AND having a urine drug screen (UDS) that is positive for BUP at the 3-month timepoint. The number/percentage of participants who demonstrate BUP adherence will be summarized by arm.

    Time frame: Baseline to 3-months following intervention

  2. 6-month Buprenorphine Treatment Retention (6-month retention)

    Buprenorphine (BUP) treatment retention at 6-months is a composite measure and will be defined as participants meeting the primary outcome AND having an active BUP prescription at the 1-month, 3-month, and 6-month timepoints.

    Time frame: From baseline to 6-months following intervention

  3. Treatment and Recovery Activities

    Treatment and Recovery activities will be measured using the Treatment Effectiveness Assessment (TEA). The TEA is a patient-centered instrument for evaluating progress in recovery from addiction. The TEA consists of 4 items used to measure recovery progress in substance use, health, lifestyle, and community domains. Participants rate progress on a scale from 1 ("not better") to 10 ("very much better"), yielding a total score from 4-40, wherein higher scores indicate greater improvement. Results will be summarized by study arm using descriptive statistics.

    Time frame: 6-months following intervention

  4. Non-prescribed Opioid Use

    Non-prescribed opioid use will be determined by the number of self-reported days of use of heroin, fentanyl, methadone, or opioid analgesics in the prior 30 days at each study visit (1-month, 3-months, and 6-months). Results will be summarized by study arm.

    Time frame: 1-month, 3-months, and 6-months following intervention

  5. Overdose (non-fatal and fatal)

    Non-fatal overdoses will be determined based on participant self-reporting during the 6 months of study participation. Fatal overdoses will be based on data collected from available administrative records or other reliable sources. This a continuous measure and the number/percentage of both fatal and non-fatal overdoses will be summarized by study arm.

    Time frame: 6-months following intervention

  6. Mean Intervention Costs

    Mean cost (in US dollars) of buprenorphine treatment will be reported for participants in each study arm. The resource utilization and resulting cost of implementing and administering the intervention will be estimated using micro-costing analysis and participant self-report. Mean costs (in US dollars) will be summarized by study arm.

    Time frame: 6 months

  7. Health-related Quality of Life - PROPr

    Health-related Quality of Life will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Preference (PROPr) questionnaire. PROPr is a comprehensive, multi-attribute health utility measure that consolidates 7 PROMIS domains-Cognitive Function, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Social Roles-into a single score, the health utility index value. A single-attribute scoring function for each PROMIS domain is calculated, with 1 = "the utility of full health" and 0 = "the utility of that domain's disutility state. The 7 single-attribute functions are combined to produce a multi-attribute summary scoring function, where 0 = "the utility of dead" and 1 = "the utility of full health," with scores less than 0 corresponding to states judged worse than dead. Results will be summarized by study arm.

    Time frame: 1-month, 3-months, and 6-months following intervention

  8. Change in Health-related Quality of Life - QALYs

    Change in Health-related Quality of Life will be used to calculate quality-adjusted life-years (QALYs). QALYs is a measure that incorporates both duration and health-related quality-of-life into a single assessment and is used to assess cost-effectiveness. The health utility index value from the PROPr is converted into QALYs. Mean years gained from baseline to 6 months intervention will be summarized by study arm.

    Time frame: From Baseline to 6-months following intervention

  9. Cost effectiveness - incremental cost-effectiveness ratio (ICER)

    The outcome of the cost-effectiveness analysis will be the incremental cost-effectiveness ratio (ICER), calculated as the adjusted-difference in costs (i.e., mean intervention costs per arm) divided by the adjusted-difference in effectiveness (i.e., mean change in Health-related Quality of Life per arm). The outcome is reported as a ratio of the two numbers.

    Time frame: 6-months following intervention

  10. Satisfaction with BUP treatment

    Satisfaction with BUP treatment will be measured by an adapted version of the Primary Care Buprenorphine Satisfaction Scale. The adapted version will use 5 (out of 19) items, covering satisfaction with the following three domains: overall and specific service components; staff expertise, concern and responsiveness; and helpfulness of overall and specific treatment components. Items are rated on a 5-point scale with 1 indicated low satisfaction and 5 indicating high satisfaction. The mean score from the 5 items will be reported.

    Time frame: 6-months following intervention

  11. Initiation of BUP treatment

    Initiation of BUP treatment will be defined as having any self-report of taking prescribed BUP over 6 months of follow-up. Initiation of BUP treatment will be assessed as a binary ("Yes/No") variable. The number/percentage of participants who initiate BUP treatment over the 6 months of follow up will be summarized by arm.

    Time frame: Up to 6-months following intervention

  12. Retention in any MOUD treatment

    Retention in any MOUD treatment will be measured based on participant self-reporting of having been engaged in an approved MOUD treatment service at 6 months. Retention in any MOUD treatment will be assessed as a binary ("Yes/No") variable. The number/percentage of participants who demonstrate retention in any MOUD treatment at the 6 months timepoint will be summarized by arm.

    Time frame: 6-months following intervention

  13. OUD severity

    OUD severity will be measured using the Diagnostic and Statistical Manual for Opioid Use Disorder, 5th Edition (DSM-5 OUD) checklist. The DSM-5 OUD checklist consists of 11 criteria, with diagnosis and severity based on the number of symptoms met within a specified period, in this case 6 months. Scoring is calculated by counting the number of "yes" responses for the 11 criteria: mild (2-3 symptoms), moderate (4-5 symptoms), and severe (6 or more symptoms). The number participants with mild, moderate, and severe symptoms will be summarized by study arm.

    Time frame: 6-months following intervention

  14. Number of days of other substance use

    The number of days of other substance use will be measured based on participant self-reporting, using a modified version of the Addiction Severity Index. Assessments will ask separately about past-30 day use of heroin, fentanyl, methadone, buprenorphine, other opioids, benzodiazepines, other sedatives, cocaine, amphetamines, methamphetamine, cannabis, alcohol, and more than one substance. A composite measure that represents the number of days (0-30) using benzodiazepines, other sedatives, cocaine, amphetamines, methamphetamine, or alcohol will be reported as "days of other substance use".

    Time frame: 1-month, 3-months, and 6-months following intervention

  15. Depression

    Depression will be assessed using the individual Depression domain subscale from the PROMIS-PROPr instrument. The PROMIS-PROPr Depression domain subscale consists of 4 items asking participants to rate their levels of depression over the prior 7-day period. Scores are rated on a scale ranging from 1 "Never" to 5 "Always" for an overall possible raw score ranging from 4-20, such that higher scores are indicative of higher depression severity. Scores will be summarized by study arm using descriptive statistics.

    Time frame: 6-months following intervention

  16. Anxiety

    Anxiety will be assessed using the individual Anxiety domain subscale from the PROMIS-PROPr instrument. The PROMIS-PROPr Anxiety domain subscale consists of 4 items asking participants to rate their levels of anxiety over the prior 7-day period. Scores are rated on a scale ranging from 1 "Never" to 5 "Always" for an overall possible raw score ranging from 4-20, such that higher scores are indicative of higher anxiety severity. Scores will be summarized by study arm using descriptive statistics.

    Time frame: 6-months following the intervention

  17. Pain Intensity

    Pain Intensity will be assessed using the individual Pain Intensity item from the PROMIS-PROPr. The PROMIS-PROPr Pain Intensity item asks participants to rate their average intensity of pain over the prior 7-day period. Scores are rated on a scale ranging from 1 "No Pain" to 10 "Worst Pain Imaginable" for an overall possible raw score ranging from 1-10, such that higher scores are indicative of higher pain intensity. Scores will be summarized by study arm using descriptive statistics.

    Time frame: 6-months following intervention

  18. Safety Outcomes

    A composite measure of experiencing one or more Targeted Safety Event (dichotomous, yes/no), which includes opioid overdoses (non-fatal and fatal), any hospitalization, or death, will be reported as an outcome measure.

    Time frame: 6-months following intervention

07

Study locations

8 of 8 sites recruiting
  • Community Health Project Los Angeles (CHPLA)
    Los Angeles, California 90029, United States
    Recruiting
    • Site PI · Contactinfo@chpla.org · 323-380-5469
    • Amanda Cowan, MSc · Principal investigator
  • HIPS
    Washington D.C., District of Columbia 20002, United States
    Recruiting
  • CARPBR/Be Safe Syringe Program
    Baton Rouge, Louisiana 70806, United States
    Recruiting
  • Harm Reduction Sisters
    Duluth, Minnesota 55805, United States
    Recruiting
  • Alianza of New Mexico
    Roswell, New Mexico 88203, United States
    Recruiting
  • HIV Alliance
    Grants Pass, Oregon 97526, United States
    Recruiting
    • Harmony Beckett · Contacthbeckett@allianceor.org · 541-342-5088
    • Harmony Beckett · Principal investigator
    • Michaela Starr O'Leary · Sub investigator
  • Challenges, Inc/Prisma Health
    Greenville, South Carolina 29605, United States
    Recruiting
    • Liam Diaz, MPH · ContactLiam.Diaz@prismahealth.org · 864-915-2528
    • Marc Burrows, MSW, LMSW, CPSS · Sub investigator
    • Alain Litwin, MD · Principal investigator
  • Vivent Health
    Milwaukee, Wisconsin 53212, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified demographic, clinical, laboratory, survey, qualitative data collected from case report forms (CRFs) will be preserved and shared. The following data will be preserved but not shared as they may contain a large volume of personally identifiable information (PII): data derived from qualitative interviews, participant locator and other administrative forms. Likewise, data from all free-text and/or comments fields will not be shared due to the nature of the data and risk of exposing PI. Scientific data will be processed and analyzed with Statistical Analysis System (SAS) software and shared in SAS and ASCII formats.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Datasets will be available when either (1) the primary outcome paper has been accepted for publication, (2) the data has been locked for more than 18 months, or (3) the grant concludes; whichever comes first. Datasets will remain accessible via the National Institute on Drug Abuse (NIDA) Data Share contingent on NIDA's continued support of the archive. To date, NIDA Data Share has not deleted any deposited data.

Access criteria: Access to the scientific data will be controlled via a registration agreement for data use on the NIDA Data Share Website. Users will have to register a name and valid e-mail address in order to download data and to accept their responsibility for using data in accordance with the NIDA Data Share Agreement.

Data sharing details ↗ · datashare.nida.nih.gov

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Feb 2028, 18 months after the start.

Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 18 months is below that.

Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 8, 2026
StartActual
Aug 17, 2026
Primary completionEst.
Feb 2028
CompletionEst.
Jun 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact's phone or email changed: •••7173→none listed. See the current contact
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Contact Study contact's phone or email changed: •••7173→none listed. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07631598
Collaborators
National Institute on Drug Abuse (NIDA), New York University, The Emmes Company, LLC
Responsible party
Sponsor
First posted
Jun 8, 2026
Start date
Aug 17, 2026
Primary completion
Feb 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Megan M Ghiroli
Contact
mghiroli@montefiore.org
12036068136
Aaron D Fox, MD, MS
Contact
adfox@montefiore.org
Aaron D Fox, MD, MS
principal investigator · Albert Einstein College of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion